

ASX/Media Release

21 November 2019

Botanix presents at Dermatology Drug Development Summit

Key highlights

- Botanix presented at the Dermatology Drug Development Summit in Boston, USA
- Botanix shared the podium with other leading dermatology and pharmaceutical companies including speakers from LEO Pharma, Galderma, Dermavant Sciences and Sanofi
- The summit provided an opportunity to showcase Botanix's expanding dermatology pipeline and its accelerated approach to clinical development and commercialisation

Philadelphia PA and Sydney Australia, 21 November 2019: Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals Limited (ASX: BOT, "Botanix" or the "Company") is pleased to announce that Dr Bill Bosch, Executive Director and Chief Scientific Officer, presented at the 3rd Annual Dermatology Drug Development Summit held in Boston, MA, USA. The presentation titled *Topical Formulations of Cannabidiol for the Treatment of Skin Diseases* is attached to this release.

The Dermatology Drug Development Summit brings together more than 150 dermatology industry leaders globally from more than 50 leading organisations. The summit provides a valuable opportunity for dermatology professionals and leading industry stakeholders to share latest ideas and pioneering insights. The summit is a unique industry-focused forum dedicated to innovating, accelerating and sharing pharmaceutical best practice on the development and commercialisation of new dermatological drugs in the treatment of high unmet needs.

Botanix shared the podium with LEO Pharma, Galderma, Dermavant Sciences, Sanofi and other leading pharmaceutical and biotechnology executives, academic researchers and industry experts. Botanix's presentation highlighted its novel approach to maximising drug delivery through its proprietary drug delivery technology, Permetrex™. The Company also took the opportunity to provide an update on its clinical development pipeline.

Dr Bill Bosch, Executive Director and Chief Scientific Officer, commented: "The annual Dermatology Drug Development Summit provided us a great opportunity to showcase Botanix's unique approach for the treatment of serious skin diseases including acne and atopic dermatitis. It is well understood by the broader industry, that there is a significant unmet medical need for each of the indications that Botanix is targeting. Lastly, the clean safety profile of cannabidiol, combined with the anti-inflammatory, immune-modulating and antimicrobial properties represents an exciting opportunity to improve patient outcomes."

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage synthetic cannabinoid company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company's focus is the development of safe and effective topical treatments for serious skin diseases, leveraging the unique anti-inflammatory, immune modulating and antimicrobial properties of synthetic cannabidiol. Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases.

The Company has announced data from its Phase 2 acne patient study and is moving forward with its clinical program with a Phase 2 FDA meeting. A Phase 2 patient study in atopic dermatitis is on target to complete enrolment in 4Q CY2019 with data in 1Q CY2020. The Company has successfully completed a mechanism of action study for synthetic cannabidiol in skin disease, with positive data announced in June 2019 and is developing a pipeline of product candidates that leverages the antimicrobial properties of cannabidiol, with first products planned to enter the clinic in 2H CY2019.

To learn more please visit: <https://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Joel Seah

Vesparum Capital

P: +61 3 8582 4800

botanixpharma@vesparum.com

Media enquiries

Haley Chartres

Hales² Communications

P: +61 423 139 163

haley@h-squared.com.au

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Topical Formulations of Cannabidiol for the Treatment of Skin Diseases

Bill Bosch, Ph.D.
Executive Board Director and CSO
Botanix Pharmaceuticals Ltd

bbosch@botanixpharma.com
www.botanixpharma.com
+1 215 796 7471





RESTORING HEALTHY SKIN

**Botanix Pharmaceuticals
Limited (ASX:BOT)**

www.botanixpharma.com



World class team

Global team with proven experience and an unrivalled track record



Vince Ippolito

President and Executive Chairman



- COO of Anacor and Medicis with 17 years at Novartis
- More than 30 years experience in pharma with 20+ years within dermatology



Dr Michael Thurn

COO and Board Director



Operations + Regulatory

- Extensive start up life sciences experience in dermatology
- Previous MD of Spinifex Pharmaceutical, which sold to Novartis for A\$700m



Howie McKibbin

Chief Commercial Officer



- SVP of Commercial at Anacor and Medicis
- More than 20 years dermatology and pharma commercial experience



Matt Callahan

Founder and Consultant



- Developed 4 products through FDA approval and launch
- Serial founder and ex-investment director of 2 venture capital firms in life sciences



Dr Stephane Levy

Chief Medical Officer



Medical + Clinical

- Ex-CMO of Almirall US operations and VP Clinical with Sanofi and Novartis
- Broad commercial and clinical development experience



Ric Peterson

Chief Financial Officer



US Finance + Corporate

- CFO of Sienna, Novan and Medicis
- Unrivalled dermatology commercial experience across multiple companies for more than 30 years



Jack Lawler

VP Development



Development + Clinical

- 20 years clinical trial and development experience
- Most recently VP at Egalet Corporation and Director at Viropharma (Shire)



Dr Joyce Rico

Strategic Advisor



Medical, Research & Development

- Recent CMO for Novan Pharmaceuticals
- Prior experience as a Board Member for the Society of Investigative Dermatology, VP, Medical Affairs at Astellas and dermatology faculty at Duke, NYU and Northwestern



Dr Judith Plon

VP Regulatory Affairs




Regulatory

- 30 years regulatory experience with multiple FDA approved dermatology products
- Ex-AVP Global Regulatory Affairs at Sanofi

Cannabidiol (CBD)

2-[(1R,6R)-6-Isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol



Botanix products in development use only synthetic, high purity material

Over-the-counter CBD products are not what they seem

Over-the-counter (OTC) or internet purchased CBD products often contain a fraction of labelled CBD content, are not currently regulated and may come with other quality and allergenic risks¹

Product name	Manufacturer	Product type	Label claim CBD content (mg/tube)	Tested CBD content
OTC 1	Green Roads	Cream	300	24.5
OTC 2	Medix CBD	Cream	150	11.2
OTC 3	Highland Pharms	Cream	200	24.6
OTC 4	MGC Derma	Cream	Undisclosed	8.8
OTC 5	CBDMEDIC	Ointment	Undisclosed	14.9



Dr. Amy Abernethy @DrAbernethyFDA · 22h

Key questions about product safety need to be addressed. Data are needed to determine safety thresholds for CBD; datasets/information should be objective, of adequate quality and available for transparent review. Lab testing and data analyses need to be replicable.

Dr Amy Abernethy Principal Deputy Commissioner and Acting CIO – FDA²

RESEARCH LETTERS

Allergenic ingredients in commercial topical cannabinoid preparations



more NACDG allergens were found in 84% of the products; 51% had 1-2 allergens, 17% had 3-4, and 17% had ≥5 (Fig 1). The most common potential allergens were tea tree oil (40%), peppermint oil


J Am Acad Dermatol Sep 2019 Pp 847-848

1. For further details on these tests – see BOT ASX release on 26/02/19. Products purchased from internet websites of respective vendors and tested by independent laboratory testing service Tioga Research. HPLC analysis of CBD content compared labelled CBD or cannabinoid content to Tioga test results.. Botanix data on file.

2. Dr Amy Abernethy Twitter post during FDA Public Hearing “Scientific Data and Information about Products Containing Cannabis or Cannabis Derived Compounds” – 31 May 2019

Permetrex™ is a proprietary novel skin delivery technology

Enables formulation of innovative topical products¹ that deliver very high doses of drug into the layers of skin without using permeation enhancers, preservatives or irritating levels of alcohol / petrol derivatives




1. Topical dosage forms include: solutions, creams, gels, ointments, foams or pastes

Independent comparative analysis of CBD delivered¹

Data indicate that BTX 1503 significantly outperformed the other CBD topical products in delivering drug to targeted layers of the skin (*ex-vivo* model)¹

Amount of CBD permeated through skin (time elapsed 48 hours)



Relative to the closest comparator, BTX 1503 delivers >5 times as much CBD to the epidermis and >3 times as much CBD to the dermis - **significantly more than other creams and gels**

1. For further details on these tests – see BOT ASX release on 26/02/19. Skin penetration tested using franz cell human skin vessel with receiver fluid assayed for CBD content at each level (epidermis and dermis). Study conducted by Tioga Research. Botanix data on file.

Advanced dermatology pipeline with recent successful data readouts

Combination of clinical, safety and mechanism of action data from recent Botanix studies provide support to near term completion of Phase 2 atopic dermatitis study

Synthetic CBD with Permetrex™ topical technology	Product	Indication	Ph 1	Ph 1b	Ph 2	Ph 3	Status
	BTX 1503 Gel	Moderate to severe acne					Preparing for FDA end of Phase 2 meeting
	BTX 1204 Solution	Moderate atopic dermatitis					Study data 1Q CY2020
	BTX 1702 Solution	Rosacea					Study start 4Q CY2019
	BTX 1801 Gel	Antimicrobial					Successful MOA ¹ study
	BTX 1308 Ointment	Psoriasis					Successful MOA ¹ study


1. MOA: Mechanism of Action

Topical CBD is a well suited to treat skin disease


Botanix has generated strong scientific support for synthetic CBD’s anti-inflammatory and immune modulation mechanisms of actions, combined with newly identified antimicrobial effects

CBD anti-inflammatory / immune modulating effects

CBD inhibits a key cytokine which affects skin barrier disfunction



CBD attenuates a well-known cytokine which drives the inflammatory response



CBD inhibits a pathway which disrupts the signaling driving the body’s immune response




CBD antimicrobial effects


CBD is active against all tested gram +ve bacteria

Antibiotic	S. aureus all isolates (µg/mL)			MRSA ¹ (µg/mL)		MSSA ² (µg/mL)	
	MIC ₅₀	MIC ₉₀	Range	MIC ₅₀	MIC ₉₀	MIC ₅₀	MIC ₉₀
Cannabidiol	2	4	0.25 - 8	2	2	2	4
Mupirocin	0.5	0.5	0.125 - 64	0.5	0.5	0.5	0.5
Vancomycin	1	2	0.5 - 64	1	1	1	2
Daptomycin	2	4	0.5 - 16	2	2	2	4
Clindamycin	0.125	64	0.03 - 64	0.125	0.1875	0.125	64

Bacteria cannot form resistance to CBD’s rapid killing power




CBD disrupts the bacteria’s biofilm protective cover



BTX 1503: CBD mechanism of action – supported by data

BTX 1503 is a safe and well tolerated topical acne treatment that potentially addresses all the key causes of acne



1 CBD normalises sebum production

- Inhibits lipogenesis and sebocyte proliferation in response to “pro-acne” agents (androgens)¹

2 CBD inhibits keratinocyte hyperproliferation

- Antiproliferative effects mediate through PPAR agonism²

3 CBD exerts a broad anti-inflammatory effect

- Inhibits *P. acnes*³ induced p38 MAP Kinase-dependent inflammatory responses in keratinocytes^{4,5}
- Inhibits *P. acnes* induced inflammation mediated by proinflammatory cytokines TNF α , IL-1, IL-6, IL-8, and IL-12^{4,6}

4 CBD is a potent Gram-positive antibiotic

- Potent bactericidal activity against clinical isolates and antibiotic resistant strains of *P. acnes*⁷

1. Olah et al. *J Clin Invest*. 2014;124(9):3713-3724

2. Wilkinson & Williamson. *J Derm Sci*. 2007;45:87-92

3. Recently renamed *Cutibacterium acnes*

4. Based on BTX 1308 Phase 1b study and BTX 1503 Phase 1b study – BOT data on file

5. Li, Wen-Hwa et al. *Dermatology and therapy* vol. 5,1 2015: 53-66


6. Petrosino et al. *J Pharmacol Exp Ther*. 2018 Jun;365(3):652-663

7. Based on University of Queensland testing – BOT data on file

Phase 1b lesion count data for BTX 1503 (acne)

A 4 week Phase 1b open-label study showed a marked reduction in inflammatory lesions and was safe and generally well tolerated

Lesion count reduction (%)¹



Other FDA approved products²

Product	Owner	Lesion count reduction (%) ³	Peak revenue ⁴
 Epiduo®	Galderma	~42%	~US\$700m
 Aczone®	Allergan	~38%	~US\$300m
BTX 1503	Botanix	~47%	-

- ✓ Combination of two drugs – benzoyl peroxide and adapalene
- ✗ Common side effects include redness, skin peeling mild burning / stinging and dryness
- ✓ Few side effects
- ✗ Common side effects are site dryness and pruritus

1. Botanix BTX.2017.002 trial - Botanix data on file

2. Botanix BTX.2017.002 trial with reported 4 week data from Epiduo and Aczone as published Am J Clin Dermatol (2016) 17: 293-303 and Journal of Drugs in Dermatology (2016) Vol 15 Issue 8 P 962

3. Lesion count reduction based on average inflammatory lesion reduction at 4 weeks

4. Symphony Health solutions PHAST 2018

BTX 1503: acne – Phase 2 study


12-week randomised, double-blind, vehicle controlled study to evaluate the safety and efficacy of BTX 1503 in patients with moderate to severe acne

Design

- 5 dose groups: ~360 subjects
 - High Dose twice a day: ~90 subjects
 - High Dose once a day: ~90 subjects
 - Low Dose once a day: ~90 subjects
 - Vehicle/Control: ~90 subjects
- ~28 US and Australian dermatology sites
- Children (> 12 years) and adults
- Moderate to severe acne patients
- Treatment Period 12 weeks


Endpoints

- Primary endpoints:
 - Absolute change from Baseline to Week 12 in inflammatory lesions
- Secondary endpoints:
 - Absolute change from Baseline to Week 12 in non-inflammatory lesions
 - % change from Baseline to Week 12 in inflammatory and non-inflammatory lesions
 - Proportion of patients with at least 2 grade reduction from Baseline IGA at week 12
- Safety
 - Adverse events and local tolerability



BTX 1204: CBD mechanism of action in atopic dermatitis

Ideal therapy that addresses multiple factors of disease pathology



1. BTX 1308 Phase 1b clinical study – BOT data on file

2. Tan et al. Mol Med Rep 2017;16((6) 8883-8867

3. Egelston et al. Dermatol Onlin J. 2018 Jun 15;24 (6)


4. Based on University of Queensland testing – BOT data on file

5. Petrosino et al. J Pharmacol Exp Ther. 2018 Jun;365(3):652-663

Phase 1b study results support efficacy and safety potential

BTX 1204 was twice as effective as vehicle (with efficacy still increasing) and displayed a substantial improvement in the key signs of atopic dermatitis¹

Treatment success (%)²



Efficacy still increasing at 4 week timepoint

- Achieved treatment success similar to many competitive topical products
- Data suggests longer treatment period for BTX 1204 possible for increased efficacy

Clear separation from vehicle (placebo)

- Despite being a small study, BTX 1204 shows superiority over vehicle, starting at early time points

Excellent safety profile

- Safety and tolerability established with no burning, stinging or application site adverse events
- BTX 1204 profile allows extended dosing which remains a key challenge with most available therapies

1. Botanix data on file. Results indicated substantial reduction in key signs of AD, providing confidence that unmet needs in AD can be addressed

2. Treatment success defined as a greater than, or equal to, a 4 point improvement in the signs and symptoms of AD

BTX 1204: atopic dermatitis – Phase 2 recruiting

12-week randomised, double-blind, vehicle-controlled study to evaluate the safety and efficacy of BTX 1204 in patients with moderate to atopic dermatitis

Study Design

- 2 dose groups: ~200 subjects
 - BTX 1204: ~100 subjects
 - Vehicle/Control: ~100 subjects
- ~25 US and Australian dermatology sites
- Children (> 12 years) and adults
- Moderate AD patients
- Treatment period of 12 weeks

Endpoints

- **Primary endpoint**
 - Proportion of subjects with ISGA success defined as an ISGA score of “Clear” (0) or “Almost Clear” (1) with at least a 2 grade improvement from Baseline at Week 12
- **Secondary endpoints**
 - Change from Baseline in the Signs of AD
 - % body surface area (BSA) affected by AD
 - Time to achieve IGA success
- **Safety**
 - Adverse events and local tolerability

Data in 1Q CY2020

BTX 1702: impact of papulopustular rosacea


Papulopustular rosacea is a chronic skin disease characterised by redness (inflammation) and acne-like break-outs¹

Affects ~16m Americans³

- ~5.5% of the adult population is affected by rosacea⁴
- only 10% seek treatment²
- misdiagnosis is common^{2,5}
- 85% of patients are over 30 years old and have multiple co-morbidities and sensitivities to treatments⁶

Clearly identified unmet medical need²

Very high emotional and psychological impact⁷



1. Blount BW, Pelletier AL. Am Fam Physician. 2002;66:435-440.

2. Prevalence of rosacea. <http://www.rosacea.org/rr/index.php>.

3. National Rosacea Society. www.rosacea.org.

4. Gether L, et al. Br J Dermatol. 2018;179:282-289

5. National Rosacea Society. http://www.rosacea.org/rr/2010/winter/article_1.php.

6. Syneos Health, Treatment Answers Prescriber Audit Data, MAT OCT18

7. Moustafa F. J Am Acad Dermatol. 2014;71:973-980.

BTX 1702 study

6 week randomised, double-blind, vehicle-controlled study to evaluate the safety and tolerability of BTX 1702 in patients with papulopustular rosacea

Study Design

- 2 dose groups: ~36 patients
 - BTX 1702 twice daily: 24 patients
 - Vehicle twice daily: 12 patients
- Australian dermatology sites
- Adults: 18 years and older
- Moderate to severe papulopustular rosacea
- Treatment period of 6 weeks
- Facial photos with Canfield imaging

Endpoints

- **Primary endpoint**
 - Safety and local tolerability assessment
- **Exploratory endpoints**
 - Absolute change and percentage change in Inflammatory lesion counts (papules & pustules)
 - Proportion of subjects with a clear (0) or almost clear (1) IGA
 - Reduction of erythema severity assessments by patients and by the Investigator

Study start 4Q CY2019

BTX 1801 - antimicrobial

Cannabidiol is a powerful new antibiotic that is effective in tests against *Staphylococcus aureus* (“staph”) and *methicillin resistant Staphylococcus aureus* (“MRSA or golden staph”)¹

Antibiotic	<i>S. aureus</i> all isolates (µg/mL)			MRSA¹ (µg/mL)		MSSA² (µg/mL)	
	MIC ₅₀	MIC ₉₀	Range	MIC ₅₀	MIC ₉₀	MIC ₅₀	MIC ₉₀
Cannabidiol	2	4	0.25 - 8	2	2	2	4
Mupirocin	0.5	0.5	0.125 – 64	0.5	0.5	0.5	0.5
Vancomycin	1	2	0.5 – 64	1	1	1	2
Daptomycin	2	4	0.5 – 16	2	2	2	4
Clindamycin	0.125	64	0.03 – 64	0.125	0.1875	0.125	64


MIC₅₀ = minimum concentration to inhibit growth of 50% of isolates

MIC₉₀ = minimum concentration to inhibit growth of 90% of isolates

MRSA = methicillin resistant *S. aureus*

MSSA = methicillin susceptible *S. aureus*

Antibiotic Minimum Inhibitory Concentration (MIC) daily variability²



1. Based on University of Queensland testing – BOT data on file

2. Based on average of 8 replicates (University of Queensland – BOT data on file)

Summary

Cannabidiol (CBD)

- CBD is promising therapy for the treatment of various skin conditions including acne, atopic dermatitis, psoriasis, rosacea, and serious infections

Permetrex™

- Formulation technology provides a new and efficient way to deliver molecules into the skin without the use of irritating solvents or penetration enhancers that may damage skin layers

Phase 2 clinical studies

- Phase 2 clinical studies in atopic dermatitis ongoing with readout expected Q1 2020

Phase 1b clinical study

- Phase 1b clinical study in psoriasis completed; Phase 1b rosacea and anti-infective clinical studies to commence 4Q CY2019



RESTORING HEALTHY SKIN

Australian Registered Office:
50 Angove Street
North Perth WA 6006
Australia

Botanix Pharma Inc.
U.S. Corporate Office:
610 W. Germantown Pike
Suite 400
Plymouth Meeting, PA 19462
USA

Visit us

www.botanixpharma.com

Follow us on social media

